

The Paediatric IBD Porto Group



PROGRAMME

6th INTERNATIONAL SYMPOSIUM ON
PAEDIATRIC INFLAMMATORY BOWEL DISEASE

7 – 10 September 2022



Edinburgh International Conference Centre
www.pibdcongress.org



Table of Contents

	Council & Committees	04
	Welcome letter	05
	ESPGHAN Society & Membership.....	06
	Venue map Edinburgh International Conference Centre	09
	Scientific Programme	
	Programme Overview	10
	Chronological Programme	12
	List of Invited Speakers and Chairpersons	23
	Poster	
	Posterplan	24
	Poster of Distinction	25



Welcome to Edinburgh

Industry

Exhibition Plan.....	28
Congress Sponsors & Exhibitors	28
Disclosure of Sponsorships.....	29
Exhibitor & Sponsor Directory Listing	30
Satellite Symposium.....	39

General information

General information	41
---------------------------	----

Council & Committees

Paediatric IBD Porto Group

CHAIR	Richard Russell, United Kingdom
FINANCIAL AND RESEARCH LIAISON	Eytan Wine, Canada
ACADEMIC LIAISON AND MEMBER LISTS	Javier Martín de Carpi, Spain

Scientific Programme Committee

CHAIR David Wilson

FURTHER SC MEMBER
Anne Griffiths
Dan Turner
Eytan Wine
Javier Martín de Carpi
Frank Ruemmele
Lisa Gervais
Paul Henderson
Holm Uhlig
Konstantinos Gerasimidis
Lissy de Ridder
Richard Russell

Local Organising Committee: Scotland

CHAIR David Wilson

FURTHER LOC MEMBER
Lee Duff
Kat Armstrong
Richard Russell
Paul Henderson

Welcome

Welcome to the 6th PIBD Congress in Edinburgh – where history meets innovation!

Dear colleagues,

On behalf of the Organising Committees of the 6th International Symposium on Paediatric Inflammatory Bowel Disease (PIBD 2022) and of ESPGHAN, it is our pleasure to invite you to come, enjoy and contribute through your participation in the largest and most exciting **global PIBD conference**, which will take place at the **Edinburgh International Conference Centre** in Scotland from **7th to 10th September 2022**.

This important international meeting offers a unique opportunity for each of us to immerse ourselves in paediatric IBD (PIBD) among a global gathering of hundreds of paediatric gastroenterologists, scientists, nurses, dietitians, surgeons and all those who care for children and young people with IBD clinically or through research. Following the wonderful successes of the previous PIBD symposia, it is our pleasure to offer the latest congress featuring diverse clinical and practical aspects of paediatric IBD care and its science base with top worldwide speakers representing five continents and covering the multitude of key issues for PIBD management in 2022.

We are excited to present a high quality scientific programme and great networking opportunities! The main symposium itself has a scientific track as well as a clinical track to give the highest chance of meeting delegates' educational needs. For the first time at a PIBD meeting we have developed and are running both an 'IBD science' course and a 'PIBD for Industry' course on the Wednesday, together with the more traditional comprehensive clinical postgraduate course „PIBD made easy“. Together we will contribute to our goal of improving IBD patient care for children and young people around the world.

We appreciate your support and look forward to seeing you in Edinburgh in September 2022!

Yours sincerely,



David Wilson
Chair of Local Committee



Richard Russell
Paediatric IBD Porto Group Chair



Ulrich Baumann
President of ESPGHAN

Society & Membership



Become a Member

By becoming a member of ESPGHAN, you will experience and gain access to a range of benefits including an international network of specialists who promote and encourage collaboration and exchange of information within GI-, Hepatology-, Nutrition Committees, working groups and their outcomes.

Subscription to JPGN, the Journal of Pediatric Gastroenterology and Nutrition, receipt of ESPGHAN

newsletters, access to the member's area of the ESPGHAN website and discounted registration fees for the ESPGHAN Annual Meeting are among the benefits of ESPGHAN members.

According to your professional status you can choose between full, corresponding, trainee, allied-health professional and emeritus membership.

Members must have an active interest in paediatric gastroenterology and/or hepatology or nutrition (PGHN).

Key Activities

ESPGHAN Mission: to promote and protect gastrointestinal health and nutrition in children on a global scale.

ESPGHAN has three standing committees focusing on paediatric Gastroenterology, Hepatology and Nutrition (PGHN), currently hosting 20 working and special interest groups covering the majority of respective fields. All groups are accessible to ESPGHAN members.

Our Allied Health Professional Committee aims to enhance the multidisciplinary approach in PGHN in Europe, while the Young ESPGHAN

Committee promotes and supports specialist training and guides trainees towards full membership of ESPGHAN.

We also offer a variety of cutting edge educational activities, ranging from Masterclasses and Summer Schools to online based education, all accessible through minimal registration fees and overseen by the ESPGHAN Education Committee.

Our most recent undertaking, the ESPGHAN Quality of Care Initiative, aims to assess and improve quality of care in PGHN throughout Europe, ultimately improving the lives of children in PGHN care.



ESPGHAN Office

European Society for
Paediatric Gastroenterology,
Hepatology and Nutrition

office@espghan.org
www.espghan.org



ESPGHAN 55th ANNUAL MEETING

of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition

17 – 20 May 2023 • Vienna • Austria




See you in Vienna in 2023!

Venue map


Edinburgh International Conference Centre

The Exchange, Morrison Street · EH3 8EE Edinburgh · Scotland

Level 0



Level 3



Programme Overview

Time	Wednesday, 7 th September 2022			Thursday, 8 th September 2022
Room	Pentland	Sidlaw	Fintry	Pentland
08:15				
08:30				
09:00				State of the Art in Therapy
09:15				
09:30				
09:45				
10:00	Course PIBD made easy			
10:15		Course IBD Science		
10:30			Course PIBD for Industry	Coffee Break
10:45				Better together? Tandem GI-surgery talks
11:00				
11:15				
11:30				
11:45				
12:00	Lunch Break	Lunch Break	Lunch Break	
12:15				
12:30				
12:45	Lunch Break			
13:00	Course Continue	Course Continue		Poster Walks at Poster Exhibition in Lomond Hall
13:15				
13:30				
13:45				
14:00			Course Continue	Course Continue
14:15				
14:30	Afternoon Tea			
14:45	Course Continue			
15:00				
15:15				
15:30	Afternoon Tea	Course Continue	Afternoon Tea	
15:45				
16:00	Course Continue		Course Continue	
16:15				
16:30				
16:45			New Lessons in difficult areas	
17:00	Opening			
17:15	IBD directions – where are we now and where are we going?			
17:30				
17:45				
18:00				
18:15	What is hot in IBD aetiology?			
19:15	Welcome Reception			

Thursday, 8 th September 2022		Friday, 9 th September 2022		Saturday, 10 th September 2022
Sidlaw		Pentland	Sidlaw	Pentland
			Industry Symposium	
		Biologics: From then to now		Preventing difficult IBD becoming refractory
		Coffee Break		Coffee Break
		Monogenic IBD: mechanisms to therapy	Outcomes in IBD – wanted and unwanted	Cases from around the globe
				Hopes for IBD State of the Art: Prevention of IBD
				Closing
Lunch Break		Lunch Break	Industry Symposium	
	Poster Walks at Poster Exhibition in Lomond Hall			
IBD around the globe		Advances in Clinical Trials	Young PIBD Session	
		Afternoon Tea		
		IBD holistic approach	Improving IBD monitoring	
		Best Oral Presentations		
		State of the Art on emerging IBD therapies: Therapies in the IBD pipeline		

Scientific Programme

Wednesday, 07 September 2022

10:00 – 12:10 Pentland Auditorium

Course 1: PIBD made easy

Chairs: Paul Henderson (United Kingdom), Kat Armstrong (United Kingdom)

10:00	Introduction to course	Paul Henderson (United Kingdom)
10:05	Diagnostic dilemma at diagnosis – Crohn's, UC, IBDU or IBD mimic?	Nick Croft (United Kingdom)
10:30	Inducing remission at diagnosis and how to know you've been successful	Victor Manuel Navas López (Spain)
10:55	Who should be started on a biological at diagnosis?	Jochen Kammermeier (United Kingdom)
11:20	How should I counsel families when discussing thiopurines and biologicals?	Kaija-Leena Kolho (Finland)
11:45	How to use therapeutic drug monitoring effectively	Jiri Bronský (Czech Republic)

12:10 – 13:00 Lunch break

13:00 – 15:05 Pentland Auditorium

Course 1: PIBD made easy

Chairs: Sue Protheroe (United Kingdom), Paul Henderson (United Kingdom)

13:00	How to optimise mesalazine therapy in ulcerative colitis – top, tail or both?	Paul Henderson (United Kingdom)
13:25	How should I assess and manage perianal problems in Crohn's disease?	Seamus Hussey (Ireland)
13:50	Can I recognise and treat extra-intestinal manifestations of IBD better?	Paolo Lionetti (Italy)
14:15	The do's and don'ts of EEN – how to improve your success rate	Rotem Sigall-Boneh (Israel)
14:40	Acute severe colitis – when the drugs don't work	Iain Chalmers (United Kingdom)

15:05 – 15:25 Afternoon Tea

15:25 – 16:40 Pentland Auditorium

Course 1: PIBD made easy

Chairs: Paul Henderson (United Kingdom), Kaija-Leena Kolho (Finland)

15:25	Is this monogenic IBD? – tips on diagnosis and management	Dror Shouval (Israel)
15:50	When should I involve a surgeon?	Jorge Amil Dias (Portugal)
16:15	New therapies in PIBD – what are they and how do I use them?	Marla Dubinsky (USA)

Scientific Programme

10:15 – 12:40 Sidlaw

Course 2: IBD Science

Chairs: David Wilson (United Kingdom), Gwo-tzer Ho (United Kingdom)

10:15	Course Introduction	David Wilson (United Kingdom)
10:20	Translational IBD research – bench, bedside and beyond	Gwo-Tzer Ho (United Kingdom)
10:50	Macrophage behaviour in gut inflammation and fibrosis	Calum Bain (United Kingdom)
11:15	Microbiome research – fundamental for IBD and so much more	Eytan Wine (Canada)
11:45	How to build your own data-sharing and sample tracking system	Shaun Chuah (United Kingdom)
12:10	The lure of 'Big Data' – health clinical and administrative data use in IBD research	Eric Benchimol (Canada)

13:20 – 15:05 Sidlaw

Course 2: IBD Science

Chairs: David Wilson (United Kingdom), Gwo-tzer Ho (United Kingdom)

13:20	IBD – a classic T cell driven immune mediated inflammatory disease	Janneke Samsom (The Netherlands)
13:50	Single cell transcriptomic and proteomic technologies in GI research	Holm Uhlig (United Kingdom)
14:15	Running a nationwide prospective IBD cohort – top tips	Thomas Walters (Canada)
14:40	Epigenetics, IBD and the gut	Matthias Zilbauer (United Kingdom)

15:25 – 16:45 Sidlaw

Course 2: IBD Science

Chairs: David Wilson (United Kingdom), Gwo-tzer Ho (United Kingdom)

15:25	Translating nutritional epidemiology and basic science to dietary therapy in IBD	Konstantinos Gerasimidis (United Kingdom)
15:55	Developing and using IBD disease activity scores, QoL scores and PROMs	Anthony Otley (Canada)
16:20	Rapidly responding to the unknown: COVID-19 and SECURE-IBD	Michael Kappelman (USA)

10:30 – 12:10 Fintry

Course 3: PIBD for Industry

Chairs: Richard Russell (United Kingdom)

10:30	Why is PIBD different? Include initial work up, investigation and growth	Marina Aloï (Italy)
10:55	Commonly used PIBD classifications and scores	Anne Griffiths (Canada)
11:20	Standard treatments in PIBD: practical not guideline perspectives	Victoria Garrick (United Kingdom)
11:45	Nutritional management in PIBD – what is important to know?	Johan van Limbergen (The Netherlands)

13:00 – 14:30 Fintry

Course 3: PIBD for Industry

Chairs: Anne Griffiths (Canada), Richard Russell (United Kingdom)

13:00	Can genetics help with the selection of medications?	Alex Muise (Canada)
13:30	How to use anti-TNF in biologics PIBD specific situations	Javier Martin de Carpi (Spain)
14:00	How to bridge the regulatory hiatus – an exemplar (The Vedokids study)	Dan Turner (Israel)

15:00 – 16:30 Fintry

Course 3: PIBD for Industry

Chairs: Richard Russell (United Kingdom), Sally Lawrence (Canada)

15:00	What's coming next for PIBD? – view of an adult IBD expert	Charlie Lees (United Kingdom)
15:30	What have we learned and what is next? The future of PIBD clinical trials	Lissy de Ridder (The Netherlands)
16:00	Potential solutions for PIBD industry studies	Richard Russell (United Kingdom), Sally Lawrence (Canada)

17:00 – 19:10 Pentland Auditorium

Opening and Session 1: IBD directions – where are we now and where are we going?

Chairs: David Wilson (United Kingdom), Richard Russell (United Kingdom)

17:00	Opening – Welcome to Edinburgh	David Wilson, (United Kingdom)
17:05	Welcome from our ESPGHAN President	Ulrich Baumann (Germany)
IBD directions – where are we now and where are we going?		
17:10	CD	Richard Russell (United Kingdom)
17:40	UC	Dan Turner (Israel)
What is hot in IBD aetiology?		
18:10	Microbiome	Eytan Wine (Canada)
18:25	Immunology	Janneke Samsom (The Netherlands)
18:40	Genome	Holm Uhlig (United Kingdom)
18:55	Exposome	Charlie Lees (United Kingdom)

Thursday, 08 September 2022

09:00 – 10:30 Pentland Auditorium

Session 2: State of the art in therapy

Chairs: Javier Martín de Carpi (Spain), Johan van Limbergen (The Netherlands)

09:00	How to choose and sequence biologicals and new small molecule drugs in IBD	Anne Griffiths (Canada)
09:40	Best of oral O-001 · Modified Exclusive Enteral Nutrition with the Crohn Disease Exclusion Diet is effective for Induction and Maintenance of Remission in children with Crohn Disease; the DIETOMICS-CD trial	Rotem Sigall-Boneh (Israel)
09:50	Best of oral O-002 · Diet-Omics characterization of new onset treatment naïve Crohn Disease identifies factors that may contribute to disease pathogenesis	Yael Haberman (Israel)
10:00	Dietary therapy: progress in IBD	Konstantinos Gerasimidis (United Kingdom)

11:00 – 12:00 Pentland Auditorium

Session 3: Better together – when MDT working is vital

Chairs: Lisa Gervais (United Kingdom), Dan Turner (Israel)

11:00	Optimising care in perianal CD	Ailsa Hart (United Kingdom)
11:25	Mistakes and mimics: Using the full MDT to avoid the misdiagnosis of IBD	David Wilson (United Kingdom)
11:50	Panel discussion plus Q&A	

14:00 – 15:30 Pentland Auditorium

Parallel Session 4.1: Wider role of nutrition in IBD

Chairs: Konstantinos Gerasimidis (United Kingdom), Eytan Wine (Canada)

14:00	How the epidemiology of IBD points to diet and what does this means for prevention and therapy?	Rotem Sigall Boneh (Israel)
14:20	More than just weight and height: bones and muscles in IBD and the role of nutrition and inflammation	Jarod Wong (United Kingdom)
14:40	Nutritional management of complex IBD	Heather Grant (United Kingdom)
15:00	Next-generation nutritional therapy in active CD	Konstantinos Gerasimidis (United Kingdom)
15:20	Panel discussion plus Q&A	

14:00 – 15:30 Sidlaw

Parallel Session 4.2: IBD around the globe

Chairs: Christina Hauer (Austria), Mutaz Sultan (Palestine)

14:00	IBD and IBD care outside the Western world	Andy Darma (Indonesia)
14:20	PIBD challenges and lessons learned in low resource countries (tandem talk)	Mutaz Sultan (Palestine), Christina Hauer (Austria)
14:50	EBV policies around the globe	Johan van Limbergen (The Netherlands)
15:10	Challenge of IBD in TB endemic areas – Case	Panel

Chronological Programme

16:00 – 17:45 Pentland Auditorium

Session 5: New lessons in difficult areas

Chairs: Nicholas Croft (United Kingdom), Marina Aloï (Italy)

16:00	COVID-19 and IBD	Michael Kappelman (USA)
16:25	Best of oral O-003 · Colorectal Cancer in Childhood-Onset Inflammatory Bowel Disease: a Scandinavian Register-based Cohort Study, 1969–2017	Ola Olén (Sweden)
16:35	Best of oral O-004 · Long-term outcomes in paediatric-onset PSC-IBD: A retrospective Canadian cohort study	Rebecca Little (Canada)
16:45	PSC-IBD	Amanda Ricciuto (Canada)
17:10	Best of oral O-005 · Serum proteomic analysis reveals novel biomarkers associated with disease activity in pediatric patients with Crohn's disease	Dror Shouval (Israel)
17:20	Interactive case: VTE thromboprophylaxis in PIBD – only for acute severe UC?	Michael Kappelman (USA)

17:45 – 18:15 Pentland Auditorium

IBD Epidemiology State of the Art

Chairs: Paul Hendersen (United Kingdom), Kaija-Leena Kolho (Finland)

17:45	Epidemiological guide to IBD aetiology'	Eric Benchimol (Canada)
-------	--	-------------------------

Friday, 09 September 2022

08:00 – 09:00 Sidlaw

Industry-sponsored Satellite Symposium

09:00 – 10:30 Pentland Auditorium

Session 6 – Biologics: From then to now

Chairs: Marla Dubinsky (USA), Anne Griffiths (Canada)

09:00	TDM for all biologics?	Amit Assa (Israel)
09:25	What is the role for dual biologic therapy in PIBD?	Marina Aloï (Italy)
09:50	What do head to head biological trials teach us?	Dan Turner (Israel)
10:15	Panel discussion plus Q&A	

11:00 – 12:30 Pentland Auditorium

Parallel Session 7.1 – Monogenic IBD: mechanisms to therapy

Chairs: Holm Uhlig (United Kingdom), Frank Ruemmele (France)

11:00	Case-based introduction to monogenic IBD issues	Aleixo Muise (Canada)
11:25	Treatment differences between Monogenic IBD, VEOIBD and PIBD	Holm Uhlig (United Kingdom)
11:50	Immune dysregulation and epithelial defects in monogenic IBD	Bernice Lo (Qatar)
12:15	Panel discussion plus Q&A	

11:00 – 12:30 Sidlaw

Parallel Session 7.2 – Outcomes in IBD – wanted and unwanted

Chairs: Annamaria Staiano (Italy), Eric Benchimol (Canada)

11:00	Have PIBD outcomes really improved in the last 20 years? Population analyses	Ola Olén (Sweden)
11:25	PIBD cancer risk: disease or drug	Eytan Wine (Canada)
11:50	Managing infectious risk in PIBD	Javier Martín de Carpi (Spain)
12:15	Panel discussion plus Q&A	

13:00 – 14:00 Sidlaw Auditorium

Industry-sponsored Satellite Symposium

14:15 – 15:35 Pentland Auditorium

Parallel Session 8.1 – Advances in clinical trials

Chairs: Richard Russell (United Kingdom), Anne Griffiths (Canada)

14:15	Innovations in IBD trial design	Nicholas Croft (United Kingdom)
14:35	Designing and running large PIBD trials: lessons learnt	Frank Ruemmele (France)
14:55	Industry perspectives	Wallace Crandall (USA)
15:15	How to extrapolate for dosing	Robert Nelson (USA)

14:15 – 15:35 Sidlaw

Young PIBD Session

Chairs: Chris Burgess (Australia), David Wands (United Kingdom), Eileen Crowley (Canada)

14:15	An informally structured session and networking for PIBD-focused clinical and research trainees/junior PIBD-focused staff and researchers
-------	--

15:55 – 17:15 Pentland Auditorium

Parallel Session 9.1 – The IBD holistic approach

Chairs: Javier Martin de Carpi (Spain), Kat Armstrong (United Kingdom)

15:55	Functional issues in IBD	Lissy de Ridder (The Netherlands)
16:15	Are growth issues still a priority in 2022?	Johan van Limbergen (The Netherlands)
16:35	Where do patient priorities differ from clinical teams?	Lisa Gervais (United Kingdom)
16:55	Psychosocial burden	Lyndsay Hughes (United Kingdom)

15:55 – 17:15 Sidlaw

Parallel Session 9.2 – Improving IBD monitoring

Chairs: Dror Shouval (Israel), Iain Chalmers (United Kingdom)

15:55	Home-based monitoring and treatment	Patrick van Rheenen (The Netherlands)
16:15	USS, MRI and WCE in PIBD: which way forward?	Peter Lewindon (Australia)
16:45	Monitoring PIBD needs a strong Radiology and GI MDT – tandem talk	Simon McGurk, Paul Henderson (United Kingdom)

17:15 – 17:45 Pentland Auditorium

Session 9.3 – Best Oral Presentations

Chairs: David Wilson (United Kingdom), Konstantinos Gerasimidis (United Kingdom)

17:15	Best of oral O-006 · Transabdominal bowel ultrasound and clinical outcomes over one year in children with newly diagnosed Crohn's disease	Alexandra Hudson (Canada)
17:25	Best of oral O-007 · Analysis of the intergenerational epigenetic contribution and the epigenetic clock in paediatric IBD	Alexandra Noble (United Kingdom)
17:35	Best of oral O-008 · Anti-TNF Versus Immunomodulators as First Maintenance Therapy in Paediatric Crohn's Disease: A Multi-Centre Prospective Cohort Study With Propensity Score Matching	Rilla E. Schneider (Canada)

17:45 – 18:15 Pentland Auditorium

State of the art talk on emerging IBD therapies

Chairs: David Wilson (United Kingdom), Konstantinos Gerasimidis (United Kingdom)

17:45	Therapies in the IBD pipeline	Charlie Lees (United Kingdom)
-------	--------------------------------------	----------------------------------

Saturday, 10 September 2022

09:00 – 10:30 Pentland Auditorium

Session 10 – Preventing difficult IBD becoming refractory

Chairs: Amit Assa (Israel), David Wands (United Kingdom)

09:00	Translational science will allow precision IBD treatment	Matthias Zilbauer (United Kingdom)
09:25	Ulcerative proctitis	Dror Shouval (Israel)
09:40	Internal penetrating CD	Javier Martin de Carpi (Spain)
09:55	Best of oral O-009 · Tofacitinib in pediatric ulcerative colitis: a retrospective multi-center experience from the Paediatric IBD Porto group of ESPGHAN	Christos Tzivinikos (United Arab Emirates)
10:05	Targeting IBD danger signals to DAMP inflammation	Gwo-Tzer Ho (United Kingdom)

11:00 – 11:40 Pentland Auditorium

Session 11 – Cases from around the globe

Chairs: Lissy de Ridder (The Netherlands), Christina Hauer (Austria)

11:00	Case 1	
11:10	Case 2	
11:20	Case 3	
11:30	Case 4	

11:40 – 12:10 Pentland Auditorium

Hopes for IBD – State of the Art

Chairs: Richard Russell (United Kingdom), David Wilson (United Kingdom)

11:40	Prevention of IBD	Marla Dubinsky (USA)
-------	--------------------------	----------------------

12:10 – 13:00 Pentland Auditorium

Closing

David Wilson (United Kingdom), Richard Russell (United Kingdom)

12:10	Take home messages from PIBD 2022	Richard Russell (United Kingdom)
12:35	Closing ceremony including prizes	David Wilson (United Kingdom)


List of Invited Speakers and Chairpersons

Marina Aloi , Italy	Charlie Lees , United Kingdom
Jorge Amil Dias , Portugal	Peter Lewindon , Australia
Kat Armstrong , United Kingdom	Paolo Lionetti , Italy
Amit Assa , Israel	Bernice Lo , Qatar
Calum Bain , United Kingdom	Javier Martín de Carpi , Spain
Eric Benchimol , Canada	Simon McGurk , United Kingdom
Jiri Bronsky , Czech Republic	Aleixo Muise , Canada
Chris Burgess , Australia	Victor Manuel Navas López , Spain
Iain Chalmers , United Kingdom	Robert Skip Nelson , USA
Shaun Chuah , United Kingdom	Ola Olén , Sweden
Wallace Crandall , USA	Anthony Otley , Canada
Nicholas Croft , United Kingdom	Sue Protheroe , United Kingdom
Eileen Crowley , Canada	Amanda Ricciuto , Canada
Andy Darma , Indonesia	Frank Ruemmele , France
Lissy de Ridder , The Netherlands	Richard Russell , United Kingdom
Marla Dubinsky , USA	Janneke Samsom , The Netherlands
Victoria Garrick , United Kingdom	Dror Shouval , Israel
Konstantionos Gerasimidis , United Kingdom	Rotem Sigall Boneh , Israel
Lisa Gervais , United Kingdom	Annamaria Staiano , Italy
Ed Giles , Australia	Mutaz Sultan , Palestine
Heather Grant , United Kingdom	Dan Turner , Israel
Anne Griffiths , Canada	Holm Uhlig , United Kingdom
Ailsa Hart , United Kingdom	Johan E. van Limbergen , The Netherlands
Christina Hauer , Austria	Patrick van Rheenen , The Netherlands
Paul Henderson , United Kingdom	Thomas Walters , Canada
Gwo-Tzer Ho , United Kingdom	David Wands , United Kingdom
Lyndsay Hughes , United Kingdom	David Wilson , United Kingdom
Seamus Hussey , Ireland	Eytan Wine , Canada
Jochen Kammermeier , United Kingdom	Jorad Wong , United Kingdom
Kajja-Leena Kolho , Finland	Matthias Zilbauer , United Kingdom
Sally Lawrence , Canada	

PIBD2022

Poster Exhibition

Poster Exhibition Plan



Poster of Distinction

Thursday, 08 September 2022, 13:00 – 13:55 h

Poster Walk Session 1

Chairs: Amit Assa (Israel), Renz Klomberg (The Netherlands)

P-001	Heather Armstrong, Canada
	Pro-inflammatory and epithelial barrier-modulating effects of specific dietary fibres are dependent on the dietary fibre source and interaction with gut microbiota
P-007	Adi Eindor, Canada
	Paediatric inflammatory bowel disease patients with <i>Clostridioides difficile</i> infection have a disrupted gastrointestinal microbiome and more severe disease outcome
P-009	Konstantinos Gerasimidis, United Kingdom
	Gut metabolomic and compositional signatures predict response to treatment with exclusive enteral nutrition in children with active Crohn's disease
P-010	Konstantinos Gerasimidis, United Kingdom
	The bacterial and fungal microbiome of newly-diagnosed, treatment naïve children with Crohn's disease; the modifying effects of exclusive enteral nutrition and re-introduction of habitual diet
P-012	Edward Giles, Australia
	Specific microbiota drives mucosal responses in inflammatory bowel disease
P-014	Mohammed Ghiboub, Netherlands
	Tryptophan metabolite changes with diet-induced remission in paediatric crohn's disease
P-022	Dror Shouval, Israel
	Novel RIPK1 Mutations Causing Infantile-onsetIBDwith Inflammatory and Fistulizing Features
P-024	Vaios Svolos, United Kingdom
	CD-TREAT diet induces remission and improves quality of life in an open label trial in children and adults with active Crohn's disease.
P-028	Jeremy Adler, United States
	Multicentre Evaluation of Patterns of and Reasons for Biologic Discontinuation Among Children with Crohn's Disease
P-069	Renz Klomberg, Netherlands
	Early anti-TNF therapy results in higher sustained steroid free remission rates in children with newly-diagnosed Crohn's disease: a prospective observational cohort study

Poster Walk

Poster Walk Session 2

Chairs: Kaija-Leena Kolho (Finland), Chris Burgess (Australia)

P-031	Allison Bihari, Canada
	Letting Go of Control: Experience and Involvement of Parents of Young Adults with Inflammatory Bowel Disease Transitioning from Paediatric to Adult Care
P-036	Jiri Bronsky, Czech Republic
	Post-vaccination immunogenicity of BNT162b2 SARS-CoV-2 vaccine and its predictors in pediatric patients with inflammatory bowel disease
P-038	Seongjin Choi, Republic of Korea
	Epidemiology of Venous Thromboembolism in Paediatric-Onset Inflammatory Bowel Disease: A nationwide population-based study in Korea
P-041	Panagiota Chondrou, United Kingdom
	Rare and severe complications in paediatric inflammatory bowel disease: a case-control study
P-043	Ruben J. Colman, United States
	Model-Informed Precision Dosing with a Pharmacokinetic Dashboard is Now Available at the Bedside for Inflammatory Bowel Disease Patients Receiving Infliximab
P-054	Gili Focht, Israel
	The Lémann Index has insufficient validity in children: a report from the prospective multicenter ImageKids study
P-065	Panagiota Chondrou, United Kingdom
	An international prospective study of the paediatric IBD incidence: current trends and findings
P-071	Wendy J Komocsar, United States
	A Novel Dual-Company Master Protocol for the Study of IL-23 Inhibitors in Pediatric Crohn's Disease
P-074	Eric Benchimol, Canada
	Predicted Incidence to 2035 of Very Early-Onset Inflammatory Bowel Disease in Two Canadian Provinces: A Population-Based Study
P-075	Sally Lawrence, Canada
	COVID-19 vaccine-induced antibody responses in paediatric inflammatory bowel disease patients treated with anti-TNF therapy.

Poster Walk Session 3


Chairs: Dror Shouval (Israel), David Wands (United Kingdom)

P-077	Anne Levine, United States
	Prophylactic enoxaparin fails to prevent thrombosis in high-risk pediatric inflammatory bowel disease patients
P-078	Dan Turner, Israel
	Predicting pediatric IBD years before diagnosis using routine blood tests
P-081	Rona Lujan, Israel
	Does early initiation of biologics change the natural history of pediatric Crohn's disease? a nationwide study from the epi-IIRN
P-086	Massimo Martinelli, Italy
	Disease course of ulcerative proctitis in children: a population based study on behalf of the SIGENP IBD Group.
P-094	Jane Oba, Brazil
	Adolescents and young adults with IBD controlled by the STRIDE-II strategies had poor HRQL in school and work domains rather than physical impairment
P-109	Luca Scarallo, Italy
	Improvement of transmural inflammation with adalimumab versus immunomodulator maintenance therapy in pediatric Crohn's disease: single-center prospective evaluation using PICMI
P-110	Luca Scarallo, Italy
	Early pro-active therapeutic drug monitoring is associated with greater durability of infliximab response: a single center comparative analysis
P-114	Matthew Smyth, Canada
	Symptom self-reporting in Paediatric IBD: the feasibility of use for disease activity monitoring and unique paediatric considerations.
P-121	Dan Turner, Israel
	Pediatric IBD is associated with multiple medical disorders: a systematic evaluation on the nationwide epi-IIRN cohort
P-130	Stephanie Vuijk, Netherlands
	Head-to-Head Pharmacokinetic Analysis of Infliximab Mono- vs Combination Therapy in Paediatric Crohn's Disease
P-132	Anat Yerushalmy-Feler, Israel
	Safety and Potential Efficacy of Escalating Dose of Ustekinumab in Paediatric Crohn's Disease (the SPEED-UP study) - A Multicenter Study from the Paediatric IBD Porto Group of ESPGHAN

INDUSTRY

Exhibition Plan

Level -0 · Edinburgh International Conference Center (EICC)



Disclosure of Sponsorships

Please find below the contribution from members of the Pharmaceutical Codes of Practice in accordance with the respective rules and transparency regulations.

N/N COMPANY	SPONSORING AMOUNT	FUNDING TYPE
1 Eli Lilly	9.100,00 €	Silver Sponsorship Package
2 Ferring Pharmaceutical Ltd	3.600,00 €	Basic Sponsorship Package
3 Janssen-Cilag Ltd	13.000,00 €	Gold Sponsorship Package
4 Nutricia	4.600,00 €	Bronze Sponsorship Package

Congress Sponsors & Exhibitors

The organiser would like to thank the following companies for their generous support of the PIBD 2022 congress.

GOLD



SILVER



BRONZE





abbvie

We're a global biopharmaceutical company fighting the world's toughest health challenges. We're determined to rise to extraordinary challenges with innovative science and we won't stop until we find the answer.

It takes all of us to turn possibilities into medicine that reaches millions. So we partner with governments, academic institutions, scientific and advocacy groups to make it happen. Because making a remarkable impact on people's lives is our purpose and passion.

Learn more at abbvie.com

Innovation
united by a
common
purpose

People. Passion.
Possibilities.®

Booth

7

abbvie

Country
USA

More information
www.abbvie.com

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio.

For more information about AbbVie, please visit us at www.abbvie.com.

Booth

8

AMGEN®

Country
USA

More information
www.amgen.co.uk

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing, and delivering innovative human therapeutics, currently focusing on six key therapeutic areas: cardiovascular disease, oncology, bone health, neuroscience, nephrology and inflammation. A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit www.amgen.co.uk

Industry



Collaboration.



Formulation.



Destination.

At Dr Falk, we do things differently. Our focus is on people.
So for every treatment we develop, from gastroenterology
to liver disease, we do it our way.

It's a simple formula.
We call it the Dr Falk way.

www.dralk.co.uk



All things Dr Falk, together in one place.

The new community app for healthcare professionals in digestive
and metabolic diseases from Dr Falk Pharma UK.



Download the app on
<https://install.events/falkplus>

available on your desktop and mobile devices

Dr Falk Pharma UK Ltd
Unit K, Bourne End Business Park
Cores End Road
Bourne End SL8 5AS
Tel: +44 (0) 1628 536 600
Email: office@drfalkpharma.co.uk

UK--2200051 Date of preparation: March 2022

Together we *know more*.
Together we *do more*.



Booth

2



Country

Switzerland

More information

www.buhlmannlabs.ch

Calprotectin is the best marker for IBD diagnosis and therapy follow up and is useful to improve quality of life and care of children. The easy to use IBDoc® calprotectin home test that can also be embedded in remote care tools is a modern element that helps empower children and their parents to manage disease. Another core element by BÜHLMANN to support paediatric patients is the Quantum Blue® rapid test for Infliximab and Adalimumab drug levels and their antibodies. This in combination with control over inflammatory status by calprotectin is the most comprehensive IBD diagnostic and monitoring solution available today.

Booth

11



Country

United Kingdom

More information

www.dralk.co.uk

For us, every treatment is a journey

Dedicated to providing treatments for digestive and metabolic diseases in a range of formulations, the aim to make treatment as convenient as possible to improve patient outcomes.

We encourage debate and exchange between clinicians and researchers through our international and UK based meetings, providing a wealth of educational resources for HCPs and patients along with collaboration with relevant patient charities.

Now, for the first time, Dr Falk have brought everything we do together in one place. FalkPlus the new, first of its kind app for our digestive and metabolic disease community.

<https://webapp.spotme.com/welcome/falkplus>

Visit our website on www.dralk.co.uk

Together we know more
Together we do more

Industry



OPEN A WORLD OF POSSIBILITIES

**TRUST THE FORTISIP RANGE TO
HELP YOUR PATIENTS GET BACK
TO DOING THE THINGS THEY LOVE.**

The Fortisip Range offers a wide variety of formats, flavours and formulations to help support your patients' needs throughout their recovery journey.



Scan here to see
what Nutricia's range
of ONS has to offer



Accurate at time of preparation: June 2022.

This information is intended for healthcare professionals only.

The Fortisip Range are Foods for Special Medical Purposes for the dietary management of disease related malnutrition and must be used under medical supervision.

NUTRICIA
Fortisip
Range

Booth

3



Country
United Kingdom

More information
ferring.co.uk

Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Founded in 1950, privately-owned Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.

As a leader in gastroenterology, Ferring has more than 35 years' experience in research and providing the right therapies to optimise treatment outcomes for mild to moderate Ulcerative Colitis patients. Ferring is also committed to deepening our understanding of the role of the human microbiome.



Country
United Kingdom

More information
www.janssen.com/uk

About the Janssen Pharmaceutical Companies of Johnson & Johnson

At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Oncology, Immunology, Neuroscience, Infectious Diseases, Cardiovascular & Metabolic Diseases and Pulmonary Hypertension.

Learn more at www.janssen.com/uk.
Follow us at [www.twitter.com/JanssenUK](https://twitter.com/JanssenUK).

Janssen-Cilag Limited is one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Industry

SAVE THE DATE and JOIN our Symposium

Nestlé Health Science
Onsite Industry Symposium PIBD 2022 | Edinburgh - Scotland

Crohn's Disease Exclusion Diet: Translating Research into Clinical Practice

Friday, 9th September | 08h00 to 09h00 am (CEST) | Room Sidlaw

Light breakfast provided

Welcome

Chairman: Prof. Eytan Wine

Where We Are with CDED and
Where We Would Like to Go

Prof. Eytan Wine

Pediatric Gastroenterologist
Division of Pediatric Gastroenterology & Nutrition
University of Alberta, Edmonton, Canada



Real World Evidence from Patient
Who Failed to Biologics

Prof. Javier Martin De Carpi

Gastroenterology, Hepatology and Nutrition Department
Hospital Sant Joan De Deu
Barcelona, Spain



The Art of CDED: What We Have Learned
since 2019

Prof. Johan van Limbergen

Pediatric Gastroenterologist
Emma's Children Hospital
Amsterdam, The Netherlands



Use of CDED in Moderate to Severe Cases

Rotem Sigall Boneh, RD

Clinical and research dietitian
Wolfson Medical Center
Holon, Israel



Q&A



Booth

1



Country

United Kingdom

More information

www.lilly.com

Eli Lilly and Company is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. Please visit us at www.lilly.com and <http://newsroom.lilly.com/social-channels>

Booth

12+14



Country

Switzerland

More information

www.nestlehealthscience.com

Nestlé Health Science is a leader in the science of nutrition, committed to redefining the management of health. From babies to the most senior citizens, we offer solutions to fill nutritional gaps, nourish those who need extra care and provide innovative products for a healthier future across the spectrum of life. In the field of inflammatory bowel disease, we develop well adapted solutions to help patients with Crohn's Disease harness the power of nutrition to live a better life.

Industry

Booth

4



Country
United Kingdom

More information
www.nutricia.com

We believe in the power of nutrition making a positive difference to health. This belief drives our commitment to pioneer life-saving and life-changing nutritional solutions, because the right nutrition at the right time can change a health trajectory for life. We work in partnership with parents, patients, carers and healthcare professionals. Through passion and the best in class science we bring health through nutrition to as many people as possible. We never forget that millions of people – young and old – around the world rely on Nutricia every day to be able to live longer, more joyful and healthier lives.



Country
United Kingdom

More information
www.reckitt.com

Mead Johnson Nutrition, a global leader in pediatric nutrition, develops, manufactures, markets, and distributes more than 70 products in over 50 markets worldwide. The company's mission is to nourish the world's children for the best start in life. The Mead Johnson name has been associated with science-based pediatric nutrition products for over 110 years. The company's Enfa™ family of brands, including Enfamil® infant formula, is a world leading brand franchise in pediatric nutrition.

Satellite Symposium

Breakfast Symposium · Friday, 09 September 2022

Crohn's Disease Exclusion Diet: translating research into clinical practice

Time 08:00 – 09:00
Room Sidlaw Auditorium
Chair Eytan Wine (Canada)



- | | |
|-------|---|
| 08:00 | Introductions
Eytan Wine (Canada) |
| 08:02 | Where we are with CEDED and where we would like to go
Eytan Wine (Canada) |
| 08:14 | Real world evidence from patients who lost response to biologics
Javier Martin De Carpi (Spain) |
| 08:26 | The art of CEDED: what we have learned since 2019
Johan van Limbergen (The Netherlands) |
| 08:38 | Use of CEDED in moderate to severe cases
Rotem Sigall-Boneh (Israel) |
| 08:50 | Q&A
All faculty |

Lunchtime Symposium · Friday, 09 September 2022

Evolving your paediatric IBD service – opportunities for success

Time 13:00 – 14:00
Room Sidlaw Auditorium
Chair Richard Russell (United Kingdom)



- | | |
|-------|---|
| 13:00 | Introductions
Richard Russell (United Kingdom) |
| 13:05 | Evolving your paediatric IBD service – opportunities for success
Richard Russell (United Kingdom) & Lissy de Ridder (The Netherlands) |
| 13:50 | Q&A
All faculty |

This is a non-promotional educational symposium organised and sponsored by Janssen and is intended for healthcare professionals only EM-100830 | August 2022

INFORMATION FOR HEALTHCARE PROFESSIONAL USE ONLY
Breastfeeding is best

APTAMIL PEPTI SYNEO FOR THE DIETARY MANAGEMENT OF
COW'S MILK ALLERGY IN FORMULA-FED INFANTS



from your Extensively Hydrolysed Formula (EHF)


Aptamil Pepti Syneo

The only EHF with a unique combination of
pre- and probiotics (synbiotics) that work synergistically

Compared to non-synbiotic formulas¹
Aptamil Pepti Syneo has been shown to support

IMPROVED symptom management¹⁻⁴

- reduction in abdominal discomfort and wind¹
- reduction in atopic dermatitis severity^{2†,3}
- reduction in constipation^{1,2} and dry stools²



For further information visit nutricia.co.uk
or contact our Healthcare Professional
Helpline on **0800 996 1234**

IMPORTANT NOTICE: Breastfeeding is best. Aptamil Pepti Syneo is a food for special medical purposes for the dietary management of cow's milk allergy. It should only be used under medical supervision, after full consideration of the feeding options available including breastfeeding. Suitable for use as the sole source of nutrition for infants from birth, and/or as part of a balanced diet from 6 months. Refer to label for details.

References: 1. Atwal K *et al.* An extensively hydrolysed synbiotic-containing formula improves gastrointestinal outcomes in infants with non-IgE cow's milk protein allergy, already well-established on extensively hydrolysed formula. Poster Presentation. European Academy of Allergy and Clinical Immunology Food Allergy and Anaphylaxis Meeting 2020. 2. Van der Aa LB *et al.* Clin Exp Allergy. 2010;(40):795-804. 3. Browne *et al.* A synbiotic EHF may help improve atopic dermatitis-like symptoms and parental QOL in infants with non-IgE mediated cow's milk allergy. Poster Presentation. European Academy of Allergy and Clinical Immunology Paediatric Allergy and Anaphylaxis Meeting 2019. 4. Browne *et al.* A new synbiotic EHF for infants with cow's milk protein allergy is well tolerated, highly acceptable and supports good growth and intake over 28 days. Poster Presentation. British Society Allergy and Clinical Immunology Meeting 2019. 5. Van der Aa LB *et al.* Allergy. 2011;66:170-177. 6. Martin R *et al.* Benef Microbes. 2010;1(4):367-82. 7. Wopereis H *et al.* Pediatr Allergy Immunol. 2014;25:428-38. 8. Harvey BM *et al.* Pediatr Res. 2014;75:343-51.

* GOS/FOS = Galacto-oligosaccharides and fructo-oligosaccharides.

† UK 4 week single split arm study^{1,3-5}; infants with non-IgE mediated CMA, baseline non-synbiotic EHF vs Aptamil Pepti Syneo. 12 week randomised controlled trial[†]: infants with atopic dermatitis, Aptamil Pepti Syneo vs Aptamil Pepti.

‡ subgroup of n=48 infants with IgE associated atopic dermatitis.

20-186. Accurate at date of publication June 2022. © Nutricia 2020.

NUTRICIA | ALLERGY

General Information

Congress Venue

Edinburgh International Conference Center (EICC)
The Exchange, Edinburgh
EH3 8EE, Scotland

Certificate of Attendance

Delegates who have been onsite will receive their Certificate of Attendance one week after the end of the symposium via e-mail.

Congress Language

The complete scientific programme including all courses will be held in English.
A simultaneous translation will not be available.

Name Badge

Upon registration onsite, all participants will receive a name badge, which must be worn visibly for the entire duration of the congress. The name badge acts as entrance ticket for the congress. Name badges will not be reprinted. For lost badges, a fee of 25% of the original registration fee applies.

Congress Office

The congress office and registration desk are located in the Strathblane Hall at ground floor.
Phone: +49 171 8011 620

CME-CPD Credits (EACCME)

The 6th International Symposium on Paediatric Inflammatory Bowel Disease, Edinburgh, Scotland, 07/09/2022 – 10/09/2022 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®). The exact number of CME credits accredited are available on the congress website. Each

Abstracts

All abstracts accepted for presentation (oral or poster) for the 6th International Symposium on Paediatric Inflammatory Bowel Disease will be published in the Journal of Paediatric Gastroenterology and Nutrition (JPGN).

Opening Hours

Congress opening hours	Wednesday	07 th September 2022	10:00 – 20:00
	Thursday	08 th September 2022	09:00 – 18:15
	Friday	09 th September 2022	09:00 – 18:15
	Saturday	10 th September 2022	09:00 – 12:45
Registration Desk	Wednesday	07 th September 2022	08:00 – 20:00
	Thursday	08 th September 2022	08:00 – 19:00
	Friday	09 th September 2022	07:30 – 19:00
	Saturday	10 th September 2022	08:00 – 13:30
Speakers Ready Room	Wednesday	07 th September 2022	08:00 – 18:00
	Thursday	08 th September 2022	08:00 – 18:00
	Friday	09 th September 2022	08:00 – 18:00
	Saturday	10 th September 2022	08:00 – 13:00
Poster Exhibition	Wednesday	07 th September 2022	17:00 – 20:00
	Thursday	08 th September 2022	08:00 – 19:00
	Friday	09 th September 2022	07:30 – 18:00
Industry Exhibition	Wednesday	07 th September 2022	17:00 – 20:00
	Thursday	08 th September 2022	09:00 – 18:15
	Friday	09 th September 2022	09:00 – 18:15
	Saturday	10 th September 2022	09:00 – 13:00



- medical specialist can claim only those hours of credit that he/she actually spent in the educational activity.

CME-CPD Certificate

The evaluation of the conference is obligatory to obtain your CME-CPD credits. The link to the online feedback form will be sent to your e-mail address at the end of the symposium.

Please complete it and submit it before 25 September 2022 at the latest. As soon as you have completed the feedback form you can create your CME-CPD Certificate and send it to your e-mail address.

Due to the regulations of EACCME, you will not receive your certificate if you do not complete the evaluation in time.

Coffee & Lunch Breaks

Snacks and refreshments during the official break times are included in the registration fee. The catering areas are located in the Strathblane Hall.

Cloakroom

A wardrobe is provided for all delegates during the official opening hours. The cloakroom will close 30 minutes after the end of the last session and is located in the Strathblane Hall at ground floor. There you can also drop off your luggage.

Any items left here are the responsibility of the individual and ESPGHAN cannot be held accountable for any loss of personal items.

Mobile Phones

Delegates are kindly requested to keep their mobile phones on silent mode in all rooms where scientific and educational sessions are being held, as well as in and around the poster and exhibition area.

Welcome Reception

The Welcome Reception will take place at the EICC in the Industry Exhibition on Wednesday, 07 September 2022 starting 19:15 h (free of charge for congress participants). Please note that your badge serves as your entrance ticket.

ESPGHAN Office

European Society for Paediatric Gastroenterology, Hepatology and Nutrition
Rue Pellegrino Rossi 16
1201 Genève, Switzerland
office@espghan.org
www.espghan.org

Congress & Industry Organisation

EUROKONGRESS

Congress + Event + Exhibition Management

EUROKONGRESS GmbH
Schleissheimer Str. 2
80333 Munich, Germany
Phone +49 89 210 98 60
pibd@eurokongress.de
www.eurokongress.de


Programme Changes

Should last minute changes due to functional, private or organisational needs be necessary, they will be announced – when possible – on the congress website. The event organiser accepts no liability for any additional costs caused by a change of programme.

Disclaimer

Neither ESPGHAN nor EUROKONGRESS GmbH shall be liable for accidents, bodily injury, and theft as well as for additional costs due to the change of event date, location, and programme or similar. Liability for additional costs due to delays, changes or cancellations of flights, trains or other means of transport as well as due to strike action, illness, weather or environmental disasters is also excluded. It is the responsibility of each participant to arrange appropriate theft-, accident-, health- as well as travel-cancellation insurance. Participants take part at their own responsibility and risk.

AMGEN®



The toughest challenges. The most advanced science.

We fight the toughest health challenges with advanced science, putting our passion to work where the need is greatest. Because our purpose as a global biopharmaceutical company is to make a remarkable impact on people's lives.

It takes all of us to turn possibilities into medicine that reaches millions. So we partner with governments, academic institutions, scientific and advocacy groups to make it happen. Together, we're inventing the future of medicine.

Learn more at
abbvie.com

abbvie

People. Passion.
Possibilities.®